Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

NTLA Intellia Therapeutics

Watchlist
43.850
+0.620+1.43%
Close  02/06 16:00 ET
43.8500.0000.00%
Post Mkt Price 02/06 16:07 ET
High
44.240
Open
42.930
Turnover
32.54M
Low
42.410
Pre Close
43.230
Volume
745.78K
Market Cap
3.74B
P/E(TTM)
Loss
52wk High
103.056
Shares
85.23M
P/E(Static)
Loss
52wk Low
32.435
Float Cap
3.52B
Bid/Ask %
-66.67%
Historical High
202.730
Shs Float
80.25M
Volume Ratio
0.63
Historical Low
9.180
Dividend TTM
--
Div Yield TTM
--
P/B
4.18
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.93%
Amplitude
4.23%
Avg Price
43.637
Lot Size
1
Float Cap
3.52B
Bid/Ask %
-66.67%
Historical High
202.730
Shs Float
80.25M
Volume Ratio
0.63
Historical Low
9.180
Dividend TTM
--
P/B
4.18
Dividend LFY
--
Turnover Ratio
0.93%
Amplitude
4.23%
Avg Price
43.637
Lot Size
1
Price Forecast

News

Comment

Company Overview More
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
CEO: Mr. John M. Leonard, M.D.
Market: NASDAQ
Listing Date: 05/06/2016
Paper Trade More
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist